Value Dossier Agent
AI-powered co-pilot for accelerating GVD, HTA, and JCA authoring through intelligent evidence synthesis, compliant content generation, and scalable market access workflows.
Challenges We Solve
Pharma organisations face significant inefficiencies and risks in GVD creation. Five critical pain points drive escalating costs, missed deadlines, and compliance risk.
Dossier timelines extended by repetitive manual authoring cycles that slow time-to-submission.
Clinical, economic and RWE evidence is fragmented across files, making consistent claim linkage unreliable.
Health economic model assumptions and narratives are rebuilt from scratch for every market adaptation.
Gaps in evidence are identified late in the review or localisation cycle, triggering costly rework.
Adaptation across markets is managed through disconnected files, folders, and email threads with no single source of truth.
Agent Capabilities
GVD Co-Pilot combines six core capabilities that work together as an integrated authoring platform.
Automates dossier section drafting and generates payer-ready narratives from ingested clinical and RWE evidence.
Aligns value narratives to payer expectations and regulatory compliance requirements across HTA bodies.
Captures health economic model assumptions, outputs, and narratives with full traceability and audit trail.
Pre-built HTA-aligned templates with reusable content blocks that can be mixed and matched by market.
Evidence is structured once and reused across sections, versions, and local market adaptations automatically.
AI generates first drafts; SMEs validate, annotate, and approve to ensure accuracy and compliance.
Your Competitive Edge
Our proven engagement model ensures successful deployment and lasting value.
We evaluate your current state, identify opportunities, and define success metrics.
Collaborate on solution architecture tailored to your workflows and data landscape.
Deploy the agent with integration support, training, and change management.
Expand capabilities across use cases, teams, and geographies with continuous optimization.
Measurable Outcomes
FAQs
Who is this solution designed for?
Pharma Market Access and Global teams managing GVD, LVD, JCA, and HTA workflows under time and compliance pressure.
Does it replace medical writers?
No. GVD Co-Pilot is a human-in-the-loop system. AI drafts sections and surfaces evidence; subject matter experts (SMEs) validate, refine, and approve all content.
Which HTA markets and templates are supported?
The solution supports major markets including US, UK, Germany, France, Japan, and others via pre-built HTA-aligned templates with configurable content blocks.
How is evidence governed and traceable?
The Governed Evidence Layer structures evidence once and links it to claims and sections across the entire dossier. All AI-generated content carries full traceability to source documents.
Can model assumptions be reused across markets?
Yes. Embedded Economics captures model assumptions, inputs, outputs, and narratives so they can be reused and adapted without manual recreation for each market.
Blogs
Similar Case Studies
Transform Your Clinical Operations











































